New Risk • Jun 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.4m free cash flow). Negative equity (-US$90m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (CA$34.4m market cap, or US$24.8m). Ankündigung • Apr 23
Resverlogix Corp., Annual General Meeting, Jun 25, 2026 Resverlogix Corp., Annual General Meeting, Jun 25, 2026. Location: alberta, calgary Canada Ankündigung • Nov 19
Resverlogix Appoints Bradley Glass to Board of Directors Resverlogix Corp. announced the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of complex business and regulatory matters. Mr. Glass is a graduate of Wabash College and the Indiana University School of Law. Ankündigung • Apr 23
Resverlogix Corp., Annual General Meeting, Jun 30, 2025 Resverlogix Corp., Annual General Meeting, Jun 30, 2025. Location: alberta, calgary Canada New Risk • Mar 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$82m). Earnings have declined by 63% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$14.2m market cap, or US$9.89m). New Risk • Dec 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$14.0m (US$9.73m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Negative equity (-US$82m). Earnings have declined by 63% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$14.0m market cap, or US$9.73m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). New Risk • Aug 16
New major risk - Revenue and earnings growth Earnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Negative equity (-US$78m). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (CA$20.8m market cap, or US$15.2m). New Risk • Aug 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (CA$18.0m market cap, or US$13.1m). New Risk • Jul 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (CA$13.8m market cap, or US$10.0m). New Risk • Jul 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.8m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Negative equity (-US$73m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.8m market cap, or US$10.00m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). New Risk • Jun 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Negative equity (-US$73m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (CA$13.8m market cap, or US$10.0m). New Risk • Jun 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.7m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Negative equity (-US$73m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.7m market cap, or US$9.99m). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). Ankündigung • Apr 20
Resverlogix Corp., Annual General Meeting, Jun 27, 2024 Resverlogix Corp., Annual General Meeting, Jun 27, 2024. New Risk • Apr 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.1m free cash flow). Negative equity (-US$74m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Market cap is less than US$100m (CA$15.1m market cap, or US$11.1m). New Risk • Feb 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$72m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (CA$17.8m market cap, or US$13.2m). Board Change • Nov 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Director Shawn Lu was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • Aug 16
Resverlogix Corp. Announces Management Changes Resverlogix Corp. announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr. Norman Wong is retiring as CSO, effective August 15, 2022. Ankündigung • Jun 23
Resverlogix Corp. Appoints Dicky To as Director Resverlogix Corp. announced that at AGM Dicky To was elected as director of the company to hold office until the next annual meeting or until their successor is elected or appointed, unless their office is earlier vacated in accordance with the company's bylaws. Recent Insider Transactions • Jun 22
Co-Founder recently bought CA$93k worth of stock On the 17th of June, Donald McCaffrey bought around 372k shares on-market at roughly CA$0.25 per share. This was the largest purchase by an insider in the last 3 months. Donald has been a buyer over the last 12 months, purchasing a net total of CA$99k worth in shares. Ankündigung • May 10
U.S. Food and Drug Administration Grants Resverlogix Corp. Request for Type C Meeting to Review Clinical Trial Protocol for Phase 3 Study Resverlogix Corp. announced that the U.S. Food and Drug Administration has granted the Company's request for a Type C meeting to review the clinical trial protocol for its Phase 3 study of apabetalone in high-risk COVID-19 outpatients. The meeting is scheduled for early August. In response to the transformation of the COVID-19 pandemic, advancement to the Phase 3 trial will target outpatients with multiple risk factors for serious outcomes, focusing where apabetalone has the potential to impact patient outcomes. Company will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program. By targeting outpatients with multiple risk factors for serious outcomes, Company aims to lessen the strain on healthcare systems keeping COVID-19 patients out of hospitals by reducing disease severity in the short and long-term. CORAL Study Design. The Phase 3, multicenter, randomized clinical trial, entitled: A Double-Blind Placebo Controlled Study to Assess the Efficacy and Safety of Oral Company in Elderly Subjects with Covid-19 Infection and High Risk for Severe Illness and to Explore the Potential to Limit Long-Term Symptoms, will evaluate the safety and efficacy of Company in preventing serious health outcomes in high-risk COVID-19 patients. Study site selection is currently underway, with sites expected in the United States, Canada, and the Middle East. High-risk COVID-19 Patients. A recently published, large-scale analysis of electronic health records, found that individuals who have contracted COVID-19 are at significantly greater long-term risk for a broad range of negative cardiovascular outcomes, including acute coronary disease, heart attack, stroke, and heart failure, compared to those who had never had the disease . The study found elevated risks persisted long after the initial infection, even in people who were not hospitalized for COVID-19, and were most pronounced among high-risk patients including those with a history of cardiovascular disease, those with pre-existing comorbidities and those over the age of 65. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Independent Lead Director Norma Biln was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • Apr 09
Resverlogix Corp., Annual General Meeting, Jun 21, 2022 Resverlogix Corp., Annual General Meeting, Jun 21, 2022. Ankündigung • Feb 18
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada Resverlogix Corp. announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Additionally, the second Canadian site, in Calgary, Alberta, has also been initiated. A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, will also be coming on line soon. Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by regulating the expression of disease and inflammation causing genes, without altering DNA. Through this mechanism, apabetalone has the potential to address both the viral and the more deadly inflammatory aspects of COVID-19. In the randomized, open-label trial, study participants will either receive twice daily oral doses of apabetalone or, alternatively, standard of care alone. A total of 100 patients are expected to be enrolled over the coming weeks, at multiple sites in Brazil and Canada. The primary outcome measure of the study will be a change in the WHO Ordinal Scale for Clinical Improvement – a standardized method of assessing COVID-19 disease severity on an 8-point scale. Secondary endpoints will include evaluating the effect of apabetalone on biomarkers of inflammation. Ankündigung • Jan 19
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment Resverlogix Corp. announced that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19. Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by regulating the expression of disease and inflammation causing genes, without altering DNA. Through this mechanism, apabetalone has the potential to address both the viral and the more deadly inflammatory aspects of COVID-19. Ankündigung • Sep 09
Resverlogix Announces Apabetalone Meets Primary Endpoint in A Pulmonary Arterial Hypertension Pilot Study Resverlogix Corp. announces that its investigational epigenetic therapeutic apabetalone met the primary endpoint in an investigator led pulmonary arterial hypertension (PAH) pilot study, successfully completing the APPROACH-p trial (Apabetalone for Pulmonary Arterial Hypertension: A Pilot Clinical Study). Study Rationale: Apabetalone is a first-in-class epigenetic therapeutic candidate BET (BRD4) inhibitor which positively regulates and normalizes genes that cause chronic illness. There is strong evidence that BRD4 plays a key role in the pathological phenotype in PAH accounting for disease progression and that BRD4 inhibition can reverse PAH in several animal models. Intriguingly, coronary artery disease (CAD) and metabolic syndrome are more prevalent in PAH compared with the global population, suggesting a link between these diseases. Interestingly, BRD4 is also a trigger for calcification and remodeling processes and regulates transcription of lipoprotein and inflammatory factors, all of which are important in PAH and CAD. Key Findings: Apabetalone treatment was well tolerated with all patients completing trial. Apabetalone treatment improved key hemodynamic variables on top of standard of care treatment, including the primary endpoint. Study Design: Open-label trial including 7 patients with pulmonary arterial hypertension (PAH); All patients received oral apabetalone twice-daily for 16 weeks, alongside existing standard of care treatments; Primary outcome measure: Change in pulmonary vascular resistance (PVR) at 16 weeks; Key secondary outcome measures: Change in other metrics of cardiac function (pulmonary artery pressure, cardiac output, right atrial pressure, and mixed venous oxygen saturation) at 16 weeks; Change in quality-of-life measures (6-min walk distance, WHO functional class, and Emphasis-10 questionnaire) at various timepoints; Change in plasma biomarkers (including: N-terminal pro-brain natriuretic peptide, alkaline phosphatase, and inflammatory cytokines) at various timepoints; Patients were limited to those diagnosed with PAH of idiopathic/hereditary origin or associated with connective tissue disease. Executive Departure • Jul 13
Senior Vice President of Business & Corporate Development Kenneth Lebioda has left the company On the 6th of July, Kenneth Lebioda's tenure as Senior Vice President of Business & Corporate Development ended. As of March 2021, Kenneth still personally held 186.45k shares (CA$170k worth at the time). Kenneth is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 11.75 years. Ankündigung • May 06
Resverlogix Corp. announced that it expects to receive CAD 7.35426 million in funding from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Resverlogix Corp. (TSX:RVX) announced it has entered into a investment agreement for private placement of 10% secured convertible debentures for gross proceeds of $6,000,000 (CAD 7,354,260) on May 5, 2021. The transaction included participation from a subsidiary of existing investor Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399). The debenture bears interest at a rate of 10% per annum and are issued at par value. The investor may elect to convert the debenture into common shares at a conversion price equal to the lesser of CAD 0.93 per share and the 5-day volume weighted average trading price of the common shares on the date of conversion. The company granted the investor a security interest in all of its assets, including its patents and other intellectual property, as security for its obligations under the debenture. The company will complete the transaction in two equal tranches, with the first tranche scheduled to be completed upon satisfaction of all closing conditions in the next three days and the second tranche to be completed by May 31, 2021. The company will also issue 300,000 common share purchase warrants at a price of CAD 0.93 per share, exercisable for a period of four years from the first closing date of the debenture financing. The transaction is subject to customary conditions including the approval of the Toronto Stock Exchange. Ankündigung • Apr 29
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease Resverlogix Corp. announced the recent publication of an article titled: “Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “Novel Therapeutic Options for Cardiovascular Disease with CKD”. In an editorial published alongside the new research, Dr. Carmine Zoccali, and Dr. Francesca Mallamaci, Nephrology Division, Grande Ospedale Metropolitano, Reggio Calabria, Italy, contextualized these new findings, emphasizing the unmet clinical need for patients suffering from diabetes and CKD, and highlighting the potential of apabetalone to benefit this group. Publication Highlights include: In a pre-specified analysis in patients with CKD, participants in the placebo group with CKD experienced double the incidence of MACE (defined as cardiovascular death, nonfatal myocardial infarction, stroke, and hospitalization for congestive heart failure) than those without CKD; Apabetalone treatment was associated with a 52% hazard reduction for MACE events such as CVD death and Heart Failure, compared to placebo (p=0.03); early and progressive separation in events occurred between the two groups; A statistically significant reduction in alkaline phosphatase, a reported risk marker for CKD, was observed in patients with CKD after 24 weeks of apabetalone treatment (p=0.004); and In addition, fewer serious adverse events were also observed in the apabetalone treated group compared to placebo (p=0.02). Chronic Kidney Disease is associated with a high burden of cardiovascular disease and poor clinical outcomes despite current standard of care treatment options. This prespecified analysis illustrated that treatment with apabetalone, in patients with stage 3 or worse CKD, diabetes and a recent acute coronary syndrome, was associated with a lower incidence of MACE. This finding demonstrates that apabetalone may offer a safe and effective treatment option for this high-risk group of patients. Ankündigung • Mar 19
Resverlogix Corp. Provides Program Update Resverlogix Corp. announced the publishing of an article, titled: “BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection”, in Cell, a high-impact scientific journal. This comes following completion of the peer-review process for previously announced findings. Cell is ranked first out of 298 journals in "Biochemistry & Molecular Biology" (Clarivate Analytics, 2019). Apabetalone is an investigational, phase 3 clinical candidate with safety data in more than 4,000 subjects. Resverlogix has announced plans for an open-label study to assess the safety and efficacy of apabetalone in the treatment of COVID-19. As previously announced, an article published on March 23, 2020 revealed the interaction between SARS-CoV-2 (COVID-19) protein E with BET proteins. Following this finding, Resverlogix put out a call for collaborations, resulting in multiple partnerships, and in parallel initiated in-house preclinical research to further characterize and investigate apabetalone’s efficacy in treating COVID-19 infection. The results of the collaborative research efforts have uncovered that apabetalone has the potential to combat COVID-19 through a unique dual mechanism. First, apabetalone treatment prevents SARS-CoV-2 from infecting human cells, and second it reduces the inflammation and cytokine storm response which can result in organ damage and long-term negative impacts. As a result of its dual mechanism and clinical safety record, several peer-reviewedpublications have shortlisted apabetalone as a clinical candidate for COVID-19. Ankündigung • Nov 05
Resverlogix Corp. Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers Resverlogix Corp. announced highly significant findings on synergy on improved renal function, as measured by estimated glomerular filtration rate (eGFR), and glucose control, as measured by glycated hemoglobin (HbA1c), when apabetalone is combined with sodium-glucose cotransporter-2 (SGLT2) inhibitors, a leading oral anti-diabetic therapy class. These unexpected findings in the BETonMACE Phase 3 trial resulted in the filing of two additional provisional patent applications, further strengthening Resverlogix’s intellectual property portfolio. The combination of apabetalone and the SGLT2 inhibitors, in addition to standard of care medicines, resulted in a significant improvement of key renal function marker eGFR compared to SGLT2 inhibitors and placebo (p=0.05). Additionally, a significant reduction of plasma Hb1Ac was also observed in patients receiving the combination of apabetalone and the SGLT2 inhibitors, on top of standard of care treatment, compared to placebo (p<0.001). Details of these findings are planned to be submitted to a leading peer review journal in the near future. Ankündigung • Oct 16
Resverlogix Corp. Announces Presentations At Leading Scientific Conferences Resverlogix Corp. announced its participation during the following leading scientific conferences: American Society of Nephrology (ASN) Kidney Week Reimagined 2020, 13th Clinical Trials on Alzheimer's Disease (CTAD) digital event, and the American Heart Association (AHA) Scientific Sessions virtual experience, featuring OnDemand oral presentations on apabetalone. Through participation at leading industry events, the Company continues to highlight apabetalone and its ability to regulate multiple biological pathways that underlie chronic disease, as well as presenting new research related to COVID-19. Ankündigung • Oct 07
Resverlogix Corp. announced that it expects to receive CAD 13.2 million in funding Resverlogix Corp. (TSX:RVX) announced it has signed a definitive stock purchase agreement of 10,560,000 equity units at a price of CAD 1.25 per unit for gross proceeds of up to CAD 13,200,000 on October 6, 2020. Each unit will consist of one common share and one share purchase warrant. Each warrant will entitle the holder to acquire one additional share at a price of CAD 1.50 per share, for a period of nine months from the date of issuance. All securities issued under the transaction will be subject to a four month hold period from the date of issuance. The closing of the transaction is subject to satisfaction of a foreign government’s investment review, due diligence conditions, customary closing conditions and receipt of all necessary regulatory and stock exchange approvals. The transaction is expected to close on or before January 15, 2021. Is New 90 Day High Low • Sep 18
New 90-day high: CA$0.93 The company is up 41% from its price of CA$0.66 on 19 June 2020. The Canadian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period. Ankündigung • Sep 16
Resverlogix Corp. Auditor Raises 'Going Concern' Doubt Resverlogix Corp. filed its Annual on Sep 11, 2020 for the period ending Apr 30, 2020. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Ankündigung • Aug 18
Resverlogix Corp. announced that it has received CAD 2.68 million in funding from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Resverlogix Corp. (TSX:RVX) announced a private placement of 3,573,333 units at a price of CAD 0.75 per unit for gross proceeds of CAD 2,680,000 on August 14, 2020. The transaction included participation from returning investor Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399). Each unit consists of one common share and one-half of one common share warrant. Each whole warrant is exercisable at a price of CAD 1 per share for a period of 1 year from closing. The units to be issued are subject to four months hold period. The investor has acquired a total of 85,286,524 common shares and 11,466,619 warrants in the company. 
